Monographie - Carboplatin

Utolsó frissítés :
19/11/2024

Carboplatin

Kémiai szerkezet

Kereskedelmi név

A kereskedelmi név meghatározó jelentőségű: a készítmények összetétele országonként, előállítóként eltérő lehet

Acoplasic	Mexikó
Axicarb	Németország
Balidon	Colombia
Blastocarb	Chile, Colombia, Mexikó, Peru
Boplatex	Colombia, Ecuador, Mexikó
Carbip	Mexikó
Carbodex	Törökország
Carboeen	India
Carbokebir	Argentína
Carbokem	India
Carbol	Peru
Carbomedac	Svédország
Carboplat	Argentína, Mexikó, Németország
Carboplatin	Amerikai Egyesült Államok, Ausztrália, Ausztria, Belgium, Brazília, Dánia, Egyiptom, Finnország, Görögország, India, Irán, Írország, Izland, Kanada, Luxemburg, Marokkó, Szaúd-Arábiában, új-Zéland
Carboplatine	Franciaország, Marokkó, Svájc
Carboplatino	Argentína, Chile, Colombia, Spanyolország
Carbosin	Belgium, Egyiptom, Görögország, Malaysia
Cycloplatin	Lengyelország, Magyarország
Emorzym	Görögország
Megaplatin	Görögország
Nuvaplast	Mexikó
Paraplatin	Amerikai Egyesült Államok, Ausztria, Belgium, Dánia, Egyesült Arab Emírségek, Finnország, Görögország, Hollandia, Lengyelország, Luxemburg, Magyarország, Mexikó, Nagy-Britannia, Norvégia, Olaszország, Spanyolország, Svájc, Svédország
Paraplatine	Franciaország, Marokkó, Tunézia
Platinwas	Spanyolország

Irodalom : Carboplatin

	Type	publikáció
3	Napló	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
57	Napló	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
81	Napló	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Napló	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
85	Napló	Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 1716-1719.
99	Napló	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
163	Napló	Sewell GJ, Allsopp M, Collinson MP, Tyrrell C, Prentice AJ, Copplestone JA. Stability studies on admixtures of 5-fluorouracil with carboplatin and 5-fluorouracil with heparin for administration in continuous infusion regimens. J Clin Pharm Ther 1994 ; 19: 127-133.
164	Napló	Benaji B, Dine T, Luyckx M, Brunet C, Goudaliez F, Mallevais ML, Cazin M, Gressier B, Cazin JC. Stability and compatibility of cisplatin and carboplatin with PVC infusion bags. J Clin Pharm Ther 1994 ; 19: 95-100.
166	Napló	Rochard E, Barthes D, Courtois P. Stability and compatibility study of carboplatin with three portable infusion pump reservoirs. Int J Pharm 1994 ; 101: 257-262.
169	Napló	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
244	Napló	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Napló	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Napló	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
300	Napló	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Napló	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Napló	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Napló	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Napló	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
409	Napló	Cheung YW, Cradock JC, Vishnuvajjala BR, Flora KP. Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions. Am J Hosp Pharm 1987 ; 44: 124-130.
484	Napló	Northcott M, Allsopp MA, Powell H, Sewell GJ. The stability of carboplatin, diamorphine, 5-fluorouracil and mitozantrone infusions in an ambulatory pump under storage and prolonged “in use” conditions. J Clin Pharm Ther 1991 ; 16: 123-129.
486	Napló	Diaz Amador F, Sevilla Azzati E, Herreros de Tajeda y Lopez-Coterilla A. Stability of carboplatin in polyvinyl chloride bags. Am J Health-Syst Pharm 1998 ; 55: 602, 604.
492	Napló	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
645	Napló	Sewell GJ, Riley CM, Rowland CG. The stability of carboplatin in ambulatory continuous infusion regimes. J Clin Pharm Ther 1987 ; 12: 427-432.
872	Napló	Zhang YP, Xu QA, Trissel LA, Gilbert DL, Martinez F. Compatibility and stability of paclitaxel combined with cisplatin and with carboplatin in infusion solutions. Ann Pharmacotherapy 1997 ; 31: 1465-1470.
905	Napló	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Napló	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1026	Napló	Mayron D, Gennaro AR. Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: 875-881.
1410	Napló	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Napló	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Napló	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	Napló	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1520	Laboratórium	Etude de stabilité des médicaments en Ecoflac® B Braun 2001
1625	Napló	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Napló	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1667	Napló	Valière C, Arnaud P, Caroff E, Dauphin JF, Clément G, Brion F. Stability and compatibility study of a carboplatin solution in syringes for continuous ambulatory infusion. Int J Pharm 1996 ; 138: 125-128.
1734	Napló	Hadfield JA, McGown AT, Dawson MJ, Thatcher N, Fox BW. The suitability of carboplatin solutions for 14-day continuous infusion by ambulatory pump : an HPLC-dynamic FAB study. J Pharm Biomed Anal 1993 ; 11: 723-727.
1925	Napló	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1950	Napló	Trissel LA, Yanping Z. Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin and oxaliplatin during simulated Y-site administration. J Oncol Pharm Practice 2004 ; 10: 191-195.
1953	Napló	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Napló	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2108	Napló	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2203	Napló	Kaestner S, Sewell G. A sequential temperature cycling study for the investigation of carboplatin infusion stability to facilitate 'dose-banding'. J Oncol Pharm Practice 2007 ; 13: 119-126.
2242	Napló	Lederer M, Leipzig-Pagani E. A note on the solution chemistry of carboplatin in aqueous solutions. Int J Pharm 1998 ; 167, 1-2: 223-228.
2243	Napló	Pujol M, Girona V, Prat J, Munoz M, De Bolos J. Degradation pathway of carboplatin in aqueous solution. Int J Pharm 1997 ; 146: 263-269.
2244	Napló	Prat J, Pujol M, Girona V, Munoz M, Sol? L-A. Stability of carboplatin in 5% glucose solution in glass, polyethylene and polypropylene containers. J Pharm Biomed Anal 1994 ; 12, 1: 81-84.
2245	Napló	Torres F, Girona V, Puiol M, Prat J, de Bolos J. Stability of carboplatin in 5% glucose solution exposed to light. Int J Pharm 1996 ; 129: 275-277.
2247	Napló	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2253	Napló	Curis E, Provost K, Bouvet D, Nicolis I, Crauste-manciet S, Brossard D, B?nazeth S. Carboplatin and oxaliplatin decomposition in chloride medium, monitored by XAS. J Synchrotron Rad 2001 ; 8: 716-718.
2254	Napló	Curis E, Provost K, Nicolis I, Bouvet D, B?nazeth S, Crauste-Manciet S, Brion F, Brossard D. Carboplatin decomposition in aqueous solution with chloride ions monitored by X-ray absorption spectroscopy. New J Chem 2000 ; 24: 1003-1008.
2262	Napló	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3277	Napló	Yang Z, Cameron S, Paul H. Stability of Carboplatin, Paclitaxel, and Docetaxel with Acetyl-L-carnitine During Simulated Y-site Administration. Int J Pharm Compound 2012 ; 16, 1 : 82-85.
3286	Napló	Okamoto Y, Tazumi K, Sanada Y, Tsugane M, Uejima E. Light-induced Deterioration Test of Carboplatin under Clinical Settings. Yakugaku Zasshi 2010 ; 130, 10: 1369-1374.
3341	Napló	Trittler R, Jung B, Strehl E. Ist teurer immer auch besser? Analytiklabor der Apotheke unterstütz Einkauf sentcheidungen bei Carboplatin-Präparaten. Krankenhauspharmazie 2001 ; 7: 331-333.
3474	Laboratórium	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3574	Laboratórium	Ondansetron - Résumé des caractéristiques du produit Accord Healthcare France SAS 2013
3602	Laboratórium	Mesna (Uromitexan®)- Summary of Product Characteristics Baxter SAS 2013
3670	Napló	Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30.
3743	Napló	Allsopp M.A, Sewell G.J, Rowland C.G, Riley C.M, Schowen R.L. The degradation of carboplatin in aqueous solutions containing chloride or other selected nucleophiles. Int J Pharm 1991 ; 69: 197-210.
3830	Napló	Myers A.Ls, Zhang Y-P, Kawedia L, Trinh V.A, Tran H, Smith J.A, Kramer M.A. Stability study of carboplatin infusion solutions in 0.9% sodium chloride in polyvinyl chloride bags. J Oncol Pharm Practice 2016 ; 22: 31-36.
4120	Napló	Vazquez-Sanchez R, Sanchez-Rubio-Ferrandez J, Cordoba-Diaz D, Cordoba-Diaz M, Molina-Garcia T. Stability of carboplatin infusion solutions used in desensitization protocol. J Oncol Pharm Practice 2018 25,5:1076?1081
4205	Napló	Choi S, O La H, Kim K, Kim S, Hwangbo S. Stability of Carboplatin in normal saline : dependence on initial dilution concentration and storage time. J Kor Soc Hosp Pharm 2006 ;23,3:219-224
4310	Napló	Mizuta N, Nakagawa T, Yamamoto K, Nishioka T, Kume M, Makimoto H, Yano I, Minami H, Hiral M. Compatibility and Stability of Nab-Paclitaxel in Combination with Other Drugs. Kaohsiung J Med Sci 2017 ; 63, 1: E9-E16.

Mentions Légales